Clinical

Antibody and CAR-T optimisation work continues with collaboration with Garvan and support of NHMRC Grant

Antibody and CAR-T optimisation work continues with collaboration with Garvan and support of NHMRC Grant

Biosceptre2025-06-24T16:14:23+10:00February 1st, 2025|Clinical, News|

Biosceptre’s collaboration with Garvan on antibody development and optimisation continues [...]

Biosceptre secures £7m. to boost novel CAR T therapy

Biosceptre secures £7m. to boost novel CAR T therapy

Biosceptre2021-03-31T15:15:21+11:00March 9th, 2021|Clinical, Corporate, News|

Biosceptre today announced the securing of £7m. (US$9.6m.) in funds [...]

Update on Biosceptre’s Phase 1 Clinical Trial for First-in-Class Oncology Vaccine BIL06v

Update on Biosceptre’s Phase 1 Clinical Trial for First-in-Class Oncology Vaccine BIL06v

Biosceptre2019-12-12T16:00:19+11:00November 14th, 2018|Clinical|

Biosceptres' Phase I clinical trial for peptide vaccine BIL06v has [...]

Biosceptre announces positive Phase I results for BIL-010t to treat Basal Cell Carcinoma

Biosceptre2014-07-23T07:00:42+10:00July 23rd, 2014|Clinical|

Cambridge, UK, 23rd July 2014. Biosceptre, the oncology company developing antibody products

Biosceptre publishes preclinical data on nf-P2X7 in the Journal of Clinical and Cellular Immunology

Biosceptre2014-07-18T09:00:52+10:00July 18th, 2014|Clinical, Corporate|

Paper concludes Biosceptre's target nf-P2X7 is ubiquitous to all cancer [...]

Biosceptre closes AUD5m financing from existing investors

Biosceptre2014-07-09T00:00:48+10:00July 9th, 2014|Clinical, Financial|

Funds to progress Phase I development of oncology product BIL-03s [...]